of a disequilibrium in lactate production (from skeletal muscle, adipose tissue and the brain) and disposal (by the liver, kidney, and heart). Importantly, however, these circumstances do not distinguish excess lactate production from impaired lactate clearance-both of which are usually in equilibrium.
A spectrum of haemodynamic insults is prevalent in acute decompensated heart failure without cardiogenic shock 6 that can adversely affect organ systems commonly involved in lactate homeostasis. Despite this, however, elevated blood lactate is uncommon, even in patients with advanced heart failure, and may not be reflective of chronic imbalances in oxygen delivery or consumption. 7 What cannot be ignored from this analysis and other studies in potentially 'stable' patients with acute heart failure is the challenging task of recognizing heightened risk. As stated in their methods, these investigators sought to exclude patients presenting in shock or with 'clinically obvious hypoperfusion'. Despite careful clinical assessment by cardiologists or heart failure specialists, however, there were still a minority of patients with alarmingly elevated lactate levels >3 mmol/L. Of course, this is by no means a commentary on the clinical aptitude of these investigators. Rather, it serves as a sobering reminder of the challenges of risk stratifying patients with acute heart failure. Even in experienced hands, a careful clinical history and detailed physical examination have well-known limitations for estimating systemic perfusion. 8 Therefore, under the assumption that clinical instability was truly excluded, it is not surprising that even mildly elevated systemic lactate levels are independently associated with mortality in heart failure as they likely represent a more broadly disturbed homeostatic imbalance than more traditional markers of risk in heart failure (e.g. amino-terminal pro-B-type natriuretic peptide). Furthermore, results from this analysis do support several interesting hypotheses. The first is that mild elevations of lactate may be associated with subclinical hepatic dysfunction-which is not surprising given the prominent role the liver plays in lactate homeostasis. The second important observation is the association of lactate levels and endothelin-1 level, thus suggesting the importance of vascular changes on lactate homeostasis. Whether this represents the downstream effects on lactate metabolism from a secondary response of the peripheral vasculature to maintain systemic perfusion in the face of decreased cardiac performance, or rather a representation of the pleiotropic effects of imbalances in lactate metabolism on the peripheral vasculature, is unknown.
What is surprising, however, is the suggestion that 'lower' levels of 'elevated' blood lactate levels, despite the limitations of capillary blood lactate measurements, are prognostically informative. While this observation may be confounded by the spectrum of lactate levels being studied, with higher levels truly being 'high' and likely being the true drivers of risk, it is biologically plausible that even slight perturbations in the multifactorial nature of lactate homeostasis may be indicative of more clinically severe heart failure.
But, does it matter?
Thanks to these investigators, we are once again reminded that heart failure, no doubt, is a systemic disease representing the downstream effects of cardiac dysfunction. Indeed, elevated lactate is now in our armamentarium of traditional and experimental biomarkers that mark elevated risk-just another way to deliver the bad news. And similar to these other biomarkers, the implications of time course changes remain uncertain and are unanswered by this analysis. Although heart failure treatment may reduce elevated lactate levels, questions remain as to whether treatment may translate into differential benefits according to lactate level (unless the patient is in overt shock). Like other biomarkers in heart failure, there remains a lack of certainty as to how they guide heart failure therapy. 9 However, while we remain clinically irresolute towards mild perturbations in lactate homeostasis in non-critically ill individuals with heart failure, these findings from Zymliński and colleagues do solidify our preference for 'lactate-free' heart failure. 
